Previous Article | Next Article 
Molecular and Cellular Biology, February 2000, p. 1243-1253, Vol. 20, No. 4
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Identification of a Sequence Element from p53 That
Signals for Mdm2-Targeted Degradation
Jijie
Gu,
Dongli
Chen,
Jamie
Rosenblum,
Rachel M.
Rubin, and
Zhi-Min
Yuan*
Department of Cancer Cell Biology, Harvard
School of Public Health, Boston, Massachusetts 02115
Received 4 August 1999/Returned for modification 24 September
1999/Accepted 21 November 1999
 |
ABSTRACT |
The binding of Mdm2 to p53 is required for targeting p53 for
degradation. p73, however, binds to Mdm2 but is refractory to Mdm2-mediated degradation, indicating that binding to Mdm2 is not
sufficient for degradation. By utilizing the structural homology between p53 and p73, we generated p53-p73 chimeras to determine the sequence element unique to p53 essential for regulation of its stability. We found that replacing an element consisting
of amino acids 92 to 112 of p53 with the corresponding region of p73
results in a protein that is not degradable by Mdm2. Removal of amino
acids 92 to 112 of p53 by deletion also results in a non-Mdm2-degradable protein. Significantly, the finding that
swapping this fragment converts p73 from refractory to sensitive to
Mdm2-mediated degradation supports the conclusion that the amino acids
92 to 112 of p53 function as a degradation signal. We
propose that the presence of an additional protein recognizes the
degradation signal and coordinates with Mdm2 to target
p53 for degradation. Our finding opens the possibility of searching for
the additional protein, which most likely plays a critical role
in the regulation of p53 stability and therefore function.
 |
INTRODUCTION |
Normal mammalian cells respond to
DNA damage by undergoing cell cycle arrest, DNA repair, or apoptosis.
Failure to respond properly to DNA damage allows the cell to replicate
and segregate damaged DNA molecules, which can result in genetic
instability and malignant transformation (11, 21, 24, 34).
The initiation of DNA damage-induced responses largely depends on the
induction of the tumor suppressor p53, which is increased in its
stability as well as its specific activity in response to genotoxic
stress (19, 27, 31). Despite intensive research, mechanisms
that regulate p53 activity are still not completely understood. In an
unstressed cell, the tumor suppressor p53 is a short-lived protein due
to its high turnover rate and is maintained at a low level. Upon
exposure to DNA damage, p53 is activated and accumulated in the absence
of apparent changes in mRNA levels (19). It has been shown
that an increase in p53 protein levels correlates with a prolonged
half-life (25, 27, 33), indicating that control of protein
stability is an important mechanism that regulates p53 function,
although enhanced translation may also contribute to the rise in p53
protein levels (10, 30).
Mdm2, itself a transcriptional target of p53, plays a critical role in
regulation of p53 activity. Knockout of the mdm2 gene is
lethal in mice with a functional p53 gene during early
embryogenesis (16). Simultaneous deletion of both
mdm2 and p53 genes gave rise to mice that
developed normally, demonstrating that Mdm2 is essential for negative
regulation of the p53 activity during development (16). Mdm2
regulates p53 function by directly binding to the transactivation
domain (TAD) of p53 to block the transcriptional activity of p53
(2, 4, 5, 6, 29, 32, 36) and by targeting p53 for
degradation (12, 13, 22, 28). The p53 protein is degraded by
ubiquitin-mediated proteolysis (26). A recent study suggests
that Mdm2 is a member of a novel class of E3 ubiquitin ligases and can
ubiquitinate p53 in vitro using purified components of the ubiquitin
pathway (13). E3 activity by Mdm2 in vivo has not been
demonstrated. Given the fact that Mdm2 must binds to p53 in order to
target the tumor suppressor for degradation, one way to stabilize p53
in cells is by disrupting the complex between p53 and Mdm2. In line
with this notion, p53 is a phosphoprotein containing a number of
phosphorylation sites in the vicinity of the N-terminal Mdm2-binding
region. Phosphorylation of p53 by protein kinase-dependent DNA in
response to DNA damage has been shown to decrease the association of
Mdm2 and p53 (35), providing a mechanism for DNA
damage-induced accumulation of p53. In more recent studies (1,
3), however, it has been shown that p53 mutants with all
potential phosphorylation sites mutated remain responsive to DNA
damage-induced activation and to an accumulation of p53, indicating
that mechanisms other than phosphorylation can regulate p53 activation
and stability in DNA-damaged cells. While Mdm2-mediated degradation
represents a key mechanism in regulation of p53 protein levels,
stabilization of p53 in response to DNA damage implies that
Mdm2-mediated degradation of p53 must be inhibited by a mechanism that
is activated by DNA damage. A better understanding of the molecular
basis of Mdm2-mediated degradation of p53 will undoubtedly shed light
onto the mechanisms responsible for DNA damage-induced activation of p53.
The p53 protein can be divided into several well-characterized domains
(24), which include the N-terminal acidic transactivation domain (TAD), which contains the Mdm2-binding motif, a
proline-rich domain (PRD) that is important for interaction with
SH3-containing proteins, and a central sequence-specific DNA-binding
domain (DBD), and the C terminus, which contains the
oligomerization domain (OD), nuclear export and localization signals,
and a region at the extreme C terminus which is involved in the
regulation of the sequence-specific DNA-binding function. Protein
degradation is usually determined by the structure of the protein,
i.e., the degradation signal and other proteins that are involved in
the recognition of the degradation signals. Numerous attempts have been
made to investigate the sequence elements involved in the regulation of
p53 stability. Using deletion mutants of p53, it has been shown that
fusing the first 42 amino acid residues of p53 with Gal4 results in a
fusion protein that is necessary and sufficient for the degradation of
p53 by the Mdm2-mediated pathway (12). In a similar
approach, other studies have showed that in addition to the N terminus,
the OD and the extreme C terminus of p53 also contribute to the
regulation of Mdm2-directed degradation of p53 (22, 23).
Whereas the results from these studies suggest that the domains of p53
are important for p53 stability, it is still not clear which sequence
element of p53 can function as a degradation signal for Mdm2-mediated degradation.
p73, a recently identified member of the p53 family, exhibits high
sequence homology to the p53's TAD, DBD, and OD (18). The
structural similarity gives p73 the ability to activate transcription of p53-responsive promoters and induce apoptosis (17, 18). p73, however, is not induced at the protein level in response to DNA
damage (18) and is refractory to Mdm2-mediated degradation (9, 38). Thus, we hypothesize that p53 has a unique sequence element that can function as a signal for Mdm2-mediated degradation. This sequence is essential for the control of p53's stability and function.
 |
MATERIALS AND METHODS |
Cell culture and transfections.
All cells were maintained in
minimal essential medium (GIBCO-BRL) containing 10% fetal bovine serum
(Sigma), 100 U of penicillin per ml, and 100 µg of streptomycin per
ml. Transfections were performed by the calcium phosphate method
(37) for 293T, U2OS, and Saos-2 cells. Luciferase activities
were assayed 24 h posttransfection with an enhanced luciferase
assay kit (1800K; Analytical Luminescence).
Plasmids.
Vectors expressing p73
or p73
have been
reported previously (37). The p53-p73 chimeras were prepared
by a two-step PCR using primers carrying a 12-nucleotide tail of the
p53 or p73 to be fused. The point mutation mutants of p53 (R273H) and
p73 (R293H) were generated by PCR using a 20-nucleotide fragment
carrying the mutated nucleotide. The p53 or p73 deletion mutant was
prepared by two-step PCR. Restriction enzyme digestion and DNA
sequencing confirmed the identity of each construct.
Immunoprecipitation and immunoblot analysis.
Immunoprecipitations were performed as described elsewhere
(37). Cell lysates were prepared in 0.5% Triton X-100 lysis
buffer (50 mM HEPES [pH 7.5], 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM sodium orthovanadate, 1 mM dithiothreitol, 1 mM NaF, 2 mM
phenylmethysulfonyl fluoride, 10 µg each of leupeptin and aprotinin
per ml) and incubated with anti-Flag agarose beads (M5; Sigma) for 8 to
12 h. Immune complexes and whole lysates were separated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then
transferred to nitrocellulose filters. The filters were incubated with
anti-p53 (Ab-6; Oncogene Science), anti-Mdm2 (Ab-1; Oncogene Science),
anti-WAF1 (Ab-3; Oncogene Science), anti-green fluorescent protein
(anti-GFP; Clontech), and anti-Flag (M5; Sigma) antibodies. Proteins
were detected with an enhanced chemiluminescence system (NEN).
Half-life determination.
For measuring half-lives of p53,
p73, or p53-p73 chimeras, U2OS cells expressing the indicated cDNA were
treated with cycloheximide (final concentration, 40 µg/ml) and
harvested at the indicated time point. Cells were processed as
described above for lysates and Western blotting.
 |
RESULTS |
Preparation of p53-p73 chimeras.
The fact that despite its
high degree of structural homology to p53 (18) and binding
to Mdm2, p73 is refractory to Mdm2-mediated degradation (9,
38) implicates the presence of a sequence unique to p53 that is
essential for Mdm2-mediated degradation. To identify this p53 sequence,
we generated a series of p53-p73 chimeras and then tested them for
sensitivity to Mdm2-mediated degradation. The high degree of structural
homology between p53 and p73 allowed us to switch each of the p53
domains with the corresponding region of p73 without disturbing the
wild-type conformation. The chimeras were prepared (Fig. 1A) by a
two-step PCR using primers carrying the 12-nucleotide tail of the
molecules to be fused. Restriction enzyme digestion and DNA sequencing
confirmed the identity of each chimera (data not shown). To test
whether the chimeras retained wild-type function, Flag-pCDNA3 vectors
expressing the chimera were prepared and then tested for the ability to
induce p21 expression. Each of the vectors was transfected transiently into Saos-2 cells, and the cells were analyzed for induction of p21 by
Western blotting 24 h posttransfection. As shown in Fig. 1B, the levels of p21 are
induced, though to variable extents, by the expression of the chimeras
(Fig. 1B, top panel), indicating their transactivational
competence. Immunoblotting with an anti-Flag antibody exhibits
comparable levels of expression achieved for the wild-type proteins and
chimeras (Fig. 1B, middle panel). Consistent with the results from the
Western analysis, transcriptional activity assessed by the luciferase
reporter gene with the p21 promoter also demonstrated that the chimeras
are transcriptionally active (Fig. 1C).


View larger version (4848K):
[in this window]
[in a new window]
|
FIG. 1.
The p53-p73 chimeras retain transcriptional activity.
(A) The p53-p73 chimeras were prepared by switching each segment
between p53 and p73 at the indicated position with a two-step PCR using
primers carrying 12-nucleotide tails of the molecules to be fused. (B)
Saos-2 cells were cotransfected with 2.5 µg of indicated expression
vectors, and 0.5 µg of plasmid pEGFP-C1 was included as the
transfection control. Cell lysates were prepared 24 h after
transfection and subjected to immunoblotting (IB) analysis with
anti-p21 (top panel), anti-Flag (middle panel), or anti-GFP (bottom
panel). (C) Saos-2 cells were cotransfected with 0.5 µg of plasmid
p21-Luc and 2.5 µg of the construct as shown in panel B. pCDNA3-Flag empty vector was used to control the DNA amounts.
Luciferase activity was measured with a normalized protein
concentration 24 h posttransfection.
|
|
Role of the OD of p53 in Mdm2-mediated degradation.
It has
been recently reported (23) that the deletion of p53's OD
resulted in a loss of its sensitivity to degradation, which was
suggested to be related to defects in binding to Mdm2. The fact that
p73
, which is 42% identical to p53 in the OD, can form an oligomer
as well as p53 does (18) but is resistant to degradation by
Mdm2 suggests the involvement of some other factor in addition to Mdm2
binding. To assess the role of the OD in Mdm2-mediated p53 degradation,
we examined the OD-swapping chimeras (Fig. 2A) for sensitivity to
Mdm2-targeted degradation. To determine whether the domain swapping has
any impact on oligomerization, we assessed the capability of the
chimeras to form oligomers in vivo by examining protein-protein
interaction using an immunoprecipitation-Western blotting (IP-Western)
analysis. To this end, Flag-tagged p73, p53, or p53-p73 chimeras with
switched ODs were coexpressed with GFP-tagged p53. Lysates were
prepared from the transfectants 24 h posttransfection and
subjected to immunoprecipitation with an anti-Flag antibody. Anti-GFP
immunoblotting analysis of the immunocomplexes demonstrated that
GFP-p53 associates with Flag-p53 but not Flag-p73 (Fig.
2B). This observation implies that p53
forms homo-oligomers but not hetero-oligomers in vivo. Interestingly,
switching the OD between p53 and p73 results in heterocomplex
formation, as evidenced by the finding that p53 was readily detected in
the immune complex of p73
and p53 amino acids 319 to 365, a region that contains the OD of p53 [p73
-p53(aa319-364)] (Fig. 2B). This finding indicates that it is the sequence of OD that determines the
specificity of oligomerization. Similar results were observed in a
parallel experiment where Flag-tagged p73, p53, or the chimeras were
coexpressed with GFP-p73. As shown in Fig. 2C, anti-GFP immunoblotting analysis revealed that GFP-p73 associates with Flag-p73 and with the
chimera containing the OD of p73 but not with Flag-p53 or the p73
chimera with OD of p53. Taken together, the results indicate that the
OD-swapping chimeras are functional in oligomer formation. Furthermore,
our results demonstrated that both p53 and p73 can form only
homo-oligomers, consistent with what was recently reported (8).

View larger version (36K):
[in this window]
[in a new window]
|
FIG. 2.
OD of p53 does not contain the sequence element
essential for Mdm2-mediated degradation. pCDNA-Flag vectors containing
p73 , p53, or the indicated chimeras (A) were coexpressed with
GFP-p53 (B) or GFP-p73 (C). Anti-Flag immunoprecipitations were
performed with cell lysates prepared from the transfectants 24 h
posttransfection. The whole cell extracts (WCE) and anti-Flag
immunocomplexes were analyzed by immunoblotting (IB) with anti-GFP
(upper panel) or anti-Flag (lower panel). (D) Switching the OD between
p53 and p73 does not alter their sensitivity to Mdm2-mediated
degradation. Saos-2 cells were cotransfected with 2.5 µg of the
indicated vectors with or without 5 µg of pCMV-Mdm2; 0.5 µg of
plasmid pEGFP-C1 was included as the transfection control. Cell lysates
were prepared 24 h after transfection and subjected to
immunoblotting analysis with anti-Flag (top panel) or anti-GFP (bottom
panel).
|
|
If the OD of p53 is essential for Mdm2-mediated degradation, an
alteration of sensitivity to degradation by Mdm2 should result from
switching the OD between p53 and p73. To test this, each of the
OD-swapping chimeras was transfected into Saos-2 cells with or without
Mdm2; protein levels were determined by immunoblotting with an
anti-Flag antibody 24 h posttransfection. Wild-type p53 and p73
were included as controls. As expected, p53 but not p73 was degraded by
the coexpression of Mdm2 (Fig. 2D, top panel, lanes 1 to 4). Switching
the ODs between p53 and p73 had no detectable effect on their
sensitivity to Mdm2-mediated degradation. The p53-p73
(aa345-390)
chimera remained sensitive (Fig. 2D, lanes 5 and 6), and
p73
-p53(aa319-364) was still refractory (Fig. 2D, lanes 7 and 8) to
Mdm2-targeted degradation. The result indicates that the OD of p53 does
not contain the sequence element essential for Mdm2-mediated degradation.
Role of the N terminus of p53 in Mdm2-mediated degradation.
The Mdm2-binding motif of p53 is located at its N terminus and is
conserved in p73 (18). The finding that p73 binds to Mdm2 but is refractory to Mdm2-mediated degradation suggests that in addition to binding to Mdm2, another element(s) is required for Mdm2-targeted degradation. It has been reported that a small domain of
p53 at the N terminus is sufficient for its degradation by Mdm2
(12). Except for the Mdm2-binding motif, the homology
between p53 and p73 at the N terminus is much less pronounced (29%
identity), providing a potential structural basis for their distinct
response to Mdm2-targeted degradation. To examine this matter, we first assessed the sensitivity of the chimeras p53-p73
(aa1-131) and p73-p53(aa1-112) (Fig. 3A, top) to
Mdm2-mediated degradation. Strikingly, the result demonstrated that
switching the N terminus between p53 and p73 is associated with a loss
of sensitivity in p53 (Fig. 3A, middle panel, lanes 5 and 6) and gain
of sensitivity in p73 (Fig. 3A, middle panel, lanes 7 and 8) to
Mdm2-mediated degradation. This finding indicates that the N terminus
of p53, consisting of amino acids 1 to 113, is indeed sufficient for
Mdm2-targeted degradation. Interestingly, p73
-p53(aa1-112) becomes
and p53-p73
(aa1-131) remains capable of ubiquitination, which
suggests that both the N and C termini of p53 are involved in the
ubiquitination. The finding that p53-p73
(aa1-131) remains
ubiquitinated but is resistant to degradation by Mdm2 suggests that
ubiquitination and degradation are separable events.

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 3.
The N terminus of p53 contains the sequence essential
for Mdm2-mediated degradation. (A) The N-terminal 131 amino acids of
p53 are necessary and sufficient for Mdm2-mediated degradation. Saos-2
cells were cotransfected with 2.5 µg of the indicated vectors with or
without 5 µg of pCMV-Mdm2 and then analyzed as described for Fig. 2.
The position of swapping is depicted (top panel). Levels of the
proteins expressed were determined by immunoblotting (IB) with
anti-Flag (middle panel). The smaller bands are likely degraded
products. Anti-GFP immunoblotting (bottom panel) demonstrates
comparable transfection efficiency achieved. (B) The PRD but not the
TAD of p53 is required for Mdm2-mediated degradation. The p53-p73
chimeras swapped at the indicated positions (top panel) were subjected
to the analysis as described for Fig. 2. Levels of the chimeras and
transfection efficiency were determined by Western analysis with
anti-Flag (middle panel) and anti-GFP (bottom panel), respectively.
|
|
Amino acids 1 to 112 of p53 can be further divided into the TAD and PRD
(24). It was reported (12) that the
Gal4-p53(aa1-42) fusion protein, like wild-type p53, was degraded by
Mdm2, suggesting this small region of p53 is necessary and sufficient
for Mdm2-mediated reduction in protein levels. If that is the case, one
would expect a conversion of p73 from refractory to sensitive to
Mdm2-mediated degradation by replacing the TAD of p73 with that of p53.
To test this, we assessed the sensitivity of p53-p73
(aa1-54) and
p73
-p53(aa1-45) (Fig. 3B, top) to Mdm2-targeted degradation. To our
surprise, the results demonstrated that the TAD of p53 is dispensable
for Mdm2-mediated degradation (Fig. 3B, middle panel),
p53-p73
(aa1-54) remains sensitive to Mdm2-mediated degradation (Fig.
3B, lanes 5 and 6), and p73
-p53(aa1-45) is still refractory to
Mdm2-mediated degradation (Fig. 3B, lanes 7 and 8). However, switching
the PRD between p53 and p73, which results in the chimeras
p53-p73
(aa55-131) and p73
-p53(aa46-112) (Fig. 3B, top),
respectively, renders p53 refractory (Fig. 3B, lanes 9 and 10) and p73
sensitive (Fig. 3B, lanes 11 and 12) to Mdm2-mediated degradation.
Together, these results indicate that the PRD but not the TAD of p53 is
essential for its sensitivity to Mdm2-mediated degradation.
In an effort to map the minimum sequence required for Mdm2-mediated
degradation, a more refined swapping at the proline-rich region was
carried out to generate the p53-p73 chimeras as shown in Fig.
4A. We then prepared Flag-tagged vectors
expressing the chimeras to test their sensitivity to
Mdm2-targeted degradation. We first examined whether this refined
domain swapping had an effect on transcriptional activity. Each of the
vectors was transfected transiently into Saos-2 cells, and the cells
were analyzed for induction of p21 by immunoblotting with an anti-p21
antibody 24 h posttransfection. The result demonstrated that
chimeras are transcriptionally active, as shown by the induction of p21
levels (Fig. 4B, top panel). Anti-Flag immunoblotting ensured that
comparable levels of chimeras proteins were expressed (Fig. 4B, middle
panel). To assess their response to Mdm2-mediated degradation, a vector containing the chimera cDNA was transfected into Saos-2 cells with or
without coexpression of Mdm2. The result shows that the region from
amino acids 92 to 112 of p53 is required for Mdm2-mediated degradation,
as demonstrated by the observation that switching amino acids 92 to 112 of p53 with the corresponding region of p73 (amino acids 106 to 131)
rendered p73 sensitive (Fig. 4C, lanes 11 and 12) and p53 resistant to
Mdm2-mediated degradation (Fig. 4C, lanes 9 and 10). In contrast,
substitution of p53's amino acids 46 to 63 or 64 to 91 with the
corresponding p73 amino acids 55 to 75 or 76 to 104, respectively, did
not lead to any apparent alteration of their response to Mdm2-mediated
degradation (Fig. 4C, lanes 1 to 8). To rule out that the refractory
nature of p53-p73
(aa106-131) to Mdm2-mediated degradation was
due to an impaired binding to Mdm2, interaction of the chimera with
Mdm2 was examined by IP-Western analysis. As shown in Fig. 4D,
p53-p73
(aa106-131), but not Rad52, bound to Mdm2 with an affinity
comparable to that of wild-type p53, as did p73
-p53(aa92-112),
indicating no apparent effect on the Mdm2 binding from the swapping
fusion. To further determine whether the gain of resistance in p53 and
loss of resistance in p73 were due to an inhibitory effect of amino
acids 106 to 131 of p73 on degradation, we prepared a p53 deletion
mutant lacking amino acids 92 to 112 and a corresponding mutant of p73
lacking amino acids 106 to 131 to test their sensitivity to
Mdm2-mediated degradation. The result shows that removal of the amino
acids 92 to 112 of p53 is associated with a loss of sensitivity to
Mdm2-mediated degradation (Fig. 4E, lanes 5 and 6). Deletion of the
corresponding region of p73, however, had no apparent effect on
resistance to Mdm2-mediated degradation (Fig. 4E, lanes 7 and 8).
IP-Western analysis demonstrated that the deletion mutants remained
capable of binding to Mdm2 (Fig. 4F), indicating that loss of
sensitivity of the p53 deletion mutant is not due to any defect in Mdm2
binding. Taken together, the results demonstrate that in addition to
the N-terminal Mdm2-binding sequence, the 21 amino acid residues 92 to
112 of p53 form the sequence element of p53 that functions as the
degradation signal for Mdm2-mediated degradation.


View larger version (3944K):
[in this window]
[in a new window]
|
FIG. 4.
Identification of the region from amino acids 92 to 112 of p53 as an essential element for Mdm2-mediated degradation. (A) The
p53-p73 chimeras with a more refined swapping at the PRD were prepared
as described in Fig. 1 by switching each segment between p53 and p73 at
the indicated position. (B) p21 levels are induced by the expression of
the chimeras. A vector (2.5 µg) containing the indicated cDNA was
transfected into Saos-2 cells, and the transfectants were analyzed by
immunoblotting (IB) with anti-p21 (upper panel) and anti-Flag (lower
panel) 24 h posttransfection. (C) The segment from amino acids 92 to 112 of p53 is essential for Mdm2-mediated degradation. The p53-p73
chimeras with more refined swapping at the PRD were tested for
sensitivity to Mdm2-mediated degradation as described for Fig. 2.
Levels of the chimeras and transfection efficiency were determined by
Western analysis with anti-Flag (upper panel) and anti-GFP (lower
panel) respectively. (D) The p53-p73 chimeras bind to Mdm2 with an
affinity comparable to that of their wild-type counterparts.
Flag-tagged vectors expressing wild-type p53, wild-type p73, or the
indicated chimeras were coexpressed with pCMV-Mdm2. Cell lysates were
prepared 24 h posttransfection and subjected to anti-Flag
immunoprecipitation. The immunocomplexes were resolved by SDS-PAGE,
transferred onto a nitrocellulose membrane, and analyzed by
immunoblotting with anti-Mdm2 (upper panel) and anti-Flag (lower
panel). Flag-tagged Rad52 was included as a control. (E) The p53 mutant
lacking amino acids 92 to 112 is no longer sensitive to Mdm2-mediated
degradation. The p53( aa92-112) mutant prepared by a two-step PCR was
tested for sensitivity to Mdm2-mediated degradation as described in the
legend to Fig. 2. The corresponding deletion mutant of p73 was included
as a control. Levels of the proteins and transfection efficiency were
determined by Western analysis with anti-Flag (upper panel) and
anti-GFP (lower panel), respectively. (F) The p53 or p73 deletion
mutants retain the ability to bind to Mdm2. Association of the deletion
mutants with Mdm2 was examined as described for panel D.
|
|
Role of the C terminus and DBD of p53 in Mdm2-mediated
degradation.
In an unstressed cell, the p53 protein is not only at
a very low level but also in an inactive state. The extreme C-terminal region of p53 has been shown to be able to prevent DNA binding through
an allosteric mechanism (14, 15). A recent study showed that
a small deletion of the C terminus of p53 leads to a decrease of
sensitivity to Mdm2-mediated degradation (23), suggesting a
contribution of the C terminus of p53 to its stability. Since p53
activity can be allosterically regulated by its C terminus, deletion of
this region might result in some degree of alteration in the
conformation of p53, which may complicate interpretation of the
results. To clarify this issue, we assessed the Mdm2-mediated degradation with the chimeras in which the corresponding region of p73
(Fig. 5A, top panel) had replaced the C
terminus of p53. The results show that p53-p73
(aa310-495) indeed
became less sensitive to Mdm2-mediated degradation than wild-type p53
(Fig. 5A, lanes 5 and 6), but p73
-p53(aa291-393) did not become more
sensitive (Fig. 5A, lanes 7 and 8), suggesting that the C terminus of
p53 is involved in the regulation of its stability but is not the determinant for its sensitivity to Mdm2-mediated degradation. Consistent to the result reported previously (23), the DBD
of p53 does not contribute to Mdm2-mediated degradation, as evidenced by the finding that no apparent change of sensitivity to the
degradation by Mdm2 resulted from switching the DBDs between p53 and
p73 (Fig. 5B).

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 5.
Contribution of the C terminus and DBD of p53 to
Mdm2-mediated degradation. (A) The p53-p73 chimeras with their C
termini switched (top panel) were tested for sensitivity to
Mdm2-mediated degradation as described for Fig. 2. Levels of the
chimeras and transfection efficiency were determined by immunoblotting
(IB) with anti-Flag (middle panel) and anti-GFP (bottom panel),
respectively. (B) The p53-p73 chimeras with their DBDs switched (top
panel) were tested for sensitivity to Mdm2-mediated degradation as
described for panel A.
|
|
p53-p73
(aa105-131) has a prolonged and p73
-p53(aa92-113) has
a shortened half-life.
Having identified amino acids 92 to 112 of
p53 as the degradation signal to Mdm2-mediated degradation, we examined
whether the changed sensitivity to Mdm2-mediated degradation
corresponded to an altered stability by measuring the half-lives of the
proteins. The ability of p53 and p73 to induce growth arrest and
apoptosis impedes expression of the wild-type proteins. To overcome
this, we generated p53 and p73 mutants by introducing a point mutation into the DNA-binding domain (Arg273-His for p53 or corresponding Arg292-His for p73), which has been shown to result in an abrogation of
DNA binding and, therefore, of transcriptional activity (17, 20). When transiently transfected into Saos-2 cells, the mutants failed to induce p21 expression (data not shown). Because cycloheximide inhibits de novo protein synthesis, the half-life of the protein can be
determined by Western blot analysis in cells treated with the drug.
U2OS cells expressing the indicated vectors were analyzed at 0, 30, 60, 120, 180, and 300 min following addition of cycloheximide. The results
demonstrated that replacing amino acids 92 to 112 of p53 with the
corresponding region (amino acids 106 to 131) of p73 resulted in a
markedly prolonged half-life (Fig. 6A,
left middle panel). On the other hand, p73
-p53(aa92-112) exhibited a
half-life much shorter than that of wild-type p73
(Fig. 6A, right
middle panel). A significantly prolonged half-life is also evident in
the p53 deletion mutant lacking amino acids 92 to 112 (Fig. 6A, left
bottom panel). Deletion of the corresponding region of p73, however,
had no apparent effect on its half-life (Fig. 6A, right bottom panel).
Densitometric measurement of the bands from Western blots enabled the
quantitation of the proteins as a percentage of the total starting
levels (Fig. 6B). Together the results demonstrate that the region from
amino acids 92 to 112 of p53 is critical for control of p53 stability.

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 6.
Correlation of Mdm2-mediated degradation to protein
stability. The region from amino acids 92 to 112 of p53 is critical for
protein stability. U2OS cells were transfected with 2.5 µg of the
indicated vector. The cells were treated with cycloheximide (40 µg/ml) at 24 h posttransfection and then harvested at 0, 30, 60, 120, 180, or 300 min later. Lysates from the cells were analyzed by
anti-Flag Western blotting (A). Quantitation of the protein as a
percentage of the starting levels was derived from a densitometric
measurement of the Western blot signals (B).
|
|
 |
DISCUSSION |
Protein degradation is generally determined by the degradation
signal derived from the structure of the protein and other proteins
that are needed for recognition of the degradation signal. While
interaction with Mdm2 is required for targeting p53 for degradation,
the observation that p73 binds to Mdm2 but is resistant to degradation
by Mdm2 indicates the existence of an additional structural element
unique to p53 required for Mdm2-targeted degradation. Using the p53-p73
chimeras generated by switching each of p53's domains with the
corresponding region of p73, we identified amino acids 92 to 112 of p53
as the element that can function as a degradation signal for
Mdm2-mediated degradation. Replacement of amino acids 92 to
112 of p53 with the corresponding region of p73 is associated with a
loss of its response to Mdm2-mediated degradation even though the
chimera retains its capability of binding to Mdm2. In support of this
observation, removal of amino acids 92 to 112 of p53 by deletion also
results in a loss of response to Mdm2-mediated degradation, indicating
that in addition to the Mdm2-binding domain, the region from amino
acids 92 to 112 is required for degradation of p53 by Mdm2. The notion
that amino acids 92 to 112 of p53 can function as a degradation signal
for the Mdm2-mediated pathway is supported by the finding that p73
gains sensitivity to Mdm2-mediated degradation once the sequence
spanning amino acids 92 to 112 of p53 is fused to the corresponding
region of p73. Interestingly, a BLAST sequence homology search
identified no apparent sequence homologue of the degradation signal
sequence, indicating its uniqueness to p53. How this sequence element
of p53 functions as a degradation signal is not clear. We speculate
that an additional protein recognizes the sequence element and
coordinates with Mdm2 to target p53 for degradation. Study is under way
to search for the potential protein. Inhibition of Mdm2-mediated
degradation of p53 has been suggested to be a principal mechanism for
stress-induced p53 accumulation (23). Investigation of the
response of the degradation signal and its interacting protein to
genotoxic stress will likely provide insights into the role for
Mdm2-targeted degradation in stress-activated induction of p53.
It has been reported that the OD of p53 participates in regulation of
its sensitivity to Mdm2-mediated degradation (23). The
results obtained from our study with the chimeras show that switching
the OD between p53 and p73 does not have any apparent effect on
Mdm2-mediated degradation. This discrepancy could reflect a difference
in Mdm2 binding because the OD-swapping chimeras are functional in
oligomer formation (Fig. 2) and remain capable of binding to Mdm2 (not
shown) but the OD deletion mutant of p53 is impaired in its
Mdm2-binding (23). Nevertheless, our result indicates that
the OD of p53 does not contain the unique sequence element essential
for Mdm2-mediated degradation.
The contribution of the extreme C terminus of p53 to its stability is
reflected by a reduced sensitivity of the C-terminal chimera to
Mdm2-mediated degradation. There is no significant homology between the
C-terminal domains of p53 and p73 (18). Whether the
decreased degradation of the C-terminal chimera of p53 by Mdm2 is due
to an allosteric regulation remains to be determined.
In summary, we have identified the region from amino acids 92 to 112 of
p53 as the element that functions as a degradation signal for
Mdm2-mediated degradation. Our finding provides a basis on which to
search for some additional protein(s) needed for recognition of the
degradation signal. The additional protein(s) should play a critical
role in the regulation of p53 stability and will most likely be a
potential new therapeutic target for manipulation of p53 activity.
 |
ACKNOWLEDGMENTS |
This work was supported by a startup package from the Harvard
School of Public Health.
We are grateful to John B. Little for critical reading of the manuscript.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Cancer Cell Biology (Bldg. 1, Room 209), Harvard School of Public
Health, 665 Huntington Ave., Boston, MA 02115. Phone: (617) 432-0763. Fax: (617) 432-0107. E-mail: zyuan{at}hsph.harvard.edu.
 |
REFERENCES |
| 1.
|
Ashcroft, M.,
M. H. Kubbutat, and K. H. Vousden.
1999.
Regulation of p53 function and stability by phosphorylation.
Mol. Cell. Biol.
19:1751-1758[Abstract/Free Full Text].
|
| 2.
|
Barak, Y. M.,
T. Juven,
R. Haffner, and M. Oren.
1993.
Mdm2 expression is induced by wild type p53 activity.
EMBO J.
12:461-468[Medline].
|
| 3.
|
Blattner, C.,
E. Tobiasch,
M. Litfen,
H. J. Rahmsdorf, and P. Herrlich.
1999.
DNA damage induced p53 stabilization: no indication for an involvement of p53 phosphorylation.
Oncogene
18:1723-1732[CrossRef][Medline].
|
| 4.
|
Chen, J. V.,
Marechal, and A. J. Levine.
1993.
Mapping of the p53 and mdm2 interaction domains.
Mol. Cell. Biol.
13:4107-4114[Abstract/Free Full Text].
|
| 5.
|
Chen, J.,
X. Wu,
J. Lin, and A. J. Levine.
1996.
Mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein.
Mol. Cell. Biol.
16:2445-2452[Abstract].
|
| 6.
|
Chen, J.,
J. Lin, and A. J. Levine.
1995.
Regulation of transcription function of the p53 tumor suppressor by the mdm-2 oncogene.
Mol. Med.
1:142-152[Medline].
|
| 7.
|
Chen, X.,
L. J. Ko,
L. Jayaraman, and C. Prives.
1996.
p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells.
Genes Dev.
10:2438-2451[Abstract/Free Full Text].
|
| 8.
|
Davison, T. S.,
C. Vagner,
M. Kaghad,
A. Ayed,
D. Caput, and C. H. Arrowsmith.
1999.
p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53.
J. Biol. Chem.
274:18709-18714[Abstract/Free Full Text].
|
| 9.
|
Dobbelstein, M.,
S. Wienzek,
C. Konig, and J. Roth.
1999.
Inactivation of the p53-homologue p73 by the mdm2-oncoprotein.
Oncogene
18:2101-2106[CrossRef][Medline].
|
| 10.
|
Fu, L., and S. Benchimol.
1997.
Participation of the human p53 3' UTR translational repression and activation following gamma-irradiation.
EMBO J.
16:4117-4125[CrossRef][Medline].
|
| 11.
|
Gottleib, T. M., and M. Oren.
1995.
p53 in growth control and neoplasia.
Biochim. Biophys. Acta
1287:77-102.
|
| 12.
|
Haupt, Y.,
R. Maya,
A. Kazaz, and M. Oren.
1997.
Mdm2 promotes the rapid degradation of p53.
Nature
387:296-299[CrossRef][Medline].
|
| 13.
|
Honda, R.,
H. Tanaka, and H. Yasuda.
1997.
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53.
FEBS Lett.
420:25-27[CrossRef][Medline].
|
| 14.
|
Hupp, T. R.,
D. W. Meek,
C. A. Midgley, and D. P. Lane.
1993.
Activation of the cryptic DNA binding function of mutant forms of p53.
Nucleic Acids Res.
21:3167-3174[Abstract/Free Full Text].
|
| 15.
|
Hupp, T. R.,
A. Sparks, and D. P. Lane.
1995.
Small peptides activate the latent sequence-specific DNA binding function of p53.
Cell
83:237-245[CrossRef][Medline].
|
| 16.
|
Jones, S. N.,
A. E. Roe,
L. A. Donehower, and A. Bradley.
1995.
Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53.
Nature
378:206-208[CrossRef][Medline].
|
| 17.
|
Jost, C.,
M. Martin, and W. G. Kaelin.
1997.
P73 is a human p53-related protein that can induce apoptosis.
Nature
389:191-194[CrossRef][Medline].
|
| 18.
|
Kaghad, M. H.,
Bonnet,
A. Yang,
L. Creancier,
J. C. Biscan,
A. Valent,
A. Minty,
P. Chalon,
J.-M. Llias,
X. Damont,
P. Ferrara,
F. McKeon, and D. Caput.
1997.
Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers.
Cell
90:809-819[CrossRef][Medline].
|
| 19.
|
Kastan, M. B.,
O. Onyekwere,
D. Sidransky,
B. Vogelstein, and R. W. Craig.
1991.
Participation of p53 in the cellular response to DNA damage.
Cancer Res.
51:6304-6311[Medline].
|
| 20.
|
Kern, S. E.,
J. A. Pietenpol,
S. Thiagalingam,
A. Seymour,
K. W. Kinzler, and B. Vogelstein.
1992.
Oncogenetic forms of p53 inhibit p53-regulated gene expression.
Science
256:827-829[Abstract/Free Full Text].
|
| 21.
|
Ko, L. J., and C. Prives.
1996.
p53: puzzle and paradigm.
Genes Dev.
10:1054-1072[Free Full Text].
|
| 22.
|
Kubbutat, M. H.,
S. N. Jones, and K. H. Vousden.
1997.
Regulation of p53 stability by Mdm2.
Nature
387:299-303[CrossRef][Medline].
|
| 23.
|
Kubbutat, M. H. G.,
R. L. Ludwig,
M. Ashcroft, and K. H. Vousden.
1998.
Regulation of Mdm2-directed degradation by the C terminus of p53.
Mol. Cell. Biol.
18:5690-5698[Abstract/Free Full Text].
|
| 24.
|
Levine, A. J.
1997.
p53, the cellular gatekeeper for growth and division.
Cell
88:323-331[CrossRef][Medline].
|
| 25.
|
Maki, C. G., and P. M. Howley.
1997.
Ubiquitination of p53 and p21 is differentially affected by ionizing radiation and UV radiation.
Mol. Cell. Biol.
17:355-363[Abstract].
|
| 26.
|
Maki, C. G.,
J. M. Huibregtse, and P. M. Howley.
1996.
In vivo ubiquitination and proteasome-mediated degradation of p53(1).
Cancer Res.
56:2649-2654[Abstract/Free Full Text].
|
| 27.
|
Maltzman, W., and L. Czyzyk.
1984.
UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells.
Mol. Cell. Biol.
4:1689-1694[Abstract/Free Full Text].
|
| 28.
|
Midgley, C. A., and D. P. Lane.
1997.
p53 protein stability in tumor cells is not determined by mutation but is dependent on Mdm2 binding.
Oncogene
15:1179-1189[CrossRef][Medline].
|
| 29.
|
Momand, J.,
G. P. Zambetti,
D. C. Olson,
D. L. Geoge, and A. J. Levine.
1992.
The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.
Cell
69:1237-1245[CrossRef][Medline].
|
| 30.
|
Mosner, J.,
T. Mummenbrauer,
C. Bauer,
G. Sczakiel,
F. Grosse, and W. Deppert.
1995.
Negative feedback regulation of wild-type p53 biosynthesis.
EMBO J.
14:4442-4449[Medline].
|
| 31.
|
Nelson, W. G., and M. Kastan.
1994.
DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways.
Mol. Cell. Biol.
14:1815-1823[Abstract/Free Full Text].
|
| 32.
|
Oliner, J. D.,
J. A. Pietenpol,
S. Thiagalingam,
J. Gyuris,
K. W. Kinzler, and B. Vogelstein.
1993.
Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53.
Nature
362:857-860[CrossRef][Medline].
|
| 33.
|
Price, B. D., and S. K. Calderwood.
1993.
Increased sequence-specific p53-DNA binding activity after DNA damage is attenuated by phorbol esters.
Oncogene
8:3055-3062[Medline].
|
| 34.
|
Sherr, C. J.
1998.
Tumor surveillance via the ARF-p53 pathway.
Genes Dev.
12:2984-2991[Free Full Text].
|
| 35.
|
Shieh, S.-Y.,
M. Ikeda,
Y. Taya, and C. Prives.
1997.
DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2.
Cell
91:325-334[CrossRef][Medline].
|
| 36.
|
Wu, X.,
J. H. Bayle,
D. Olson, and A. J. Levine.
1993.
The p53-mdm-2 autoregulatory feedback loop.
Genes Dev.
7:1126-1132[Abstract/Free Full Text].
|
| 37.
|
Yuan, Z.-M.,
H. Shioya,
T. Ishiko,
X. Sun,
J. Gu,
Y. Y. Huang,
H. Lu,
S. Kharbanda,
R. Weichselbaum, and D. Kufe.
1999.
p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage.
Nature
399:814-817[CrossRef][Medline].
|
| 38.
|
Zeng, X.,
L. Chen,
C. A. Jost,
R. Maya,
D. Keller,
X. Wang,
W. G. Kaelin, Jr.,
M. Oren,
J. Chen, and H. Lu.
1999.
MDM2 suppresses p73 function without promoting p73 degradation.
Mol. Cell. Biol.
19:3257-3266[Abstract/Free Full Text].
|
Molecular and Cellular Biology, February 2000, p. 1243-1253, Vol. 20, No. 4
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Lopez-Pajares, V., Kim, M. M., Yuan, Z.-M.
(2008). Phosphorylation of MDMX Mediated by Akt Leads to Stabilization and Induces 14-3-3 Binding. J. Biol. Chem.
283: 13707-13713
[Abstract]
[Full Text]
-
Sasaki, M., Nie, L., Maki, C. G.
(2007). MDM2 Binding Induces a Conformational Change in p53 That Is Opposed by Heat-shock Protein 90 and Precedes p53 Proteasomal Degradation. J. Biol. Chem.
282: 14626-14634
[Abstract]
[Full Text]
-
Nie, L., Sasaki, M., Maki, C. G.
(2007). Regulation of p53 Nuclear Export through Sequential Changes in Conformation and Ubiquitination. J. Biol. Chem.
282: 14616-14625
[Abstract]
[Full Text]
-
Stuart, J. R., Gonzalez, F. H., Kawai, H., Yuan, Z.-M.
(2006). c-Abl Interacts with the WAVE2 Signaling Complex to Induce Membrane Ruffling and Cell Spreading. J. Biol. Chem.
281: 31290-31297
[Abstract]
[Full Text]
-
Morrison, R. N., Cooper, G. A., Koop, B. F., Rise, M. L., Bridle, A. R., Adams, M. B., Nowak, B. F.
(2006). Transcriptome profiling the gills of amoebic gill disease (AGD)-affected Atlantic salmon (Salmo salar L.): a role for tumor suppressor p53 in AGD pathogenesis?. Physiol. Genomics
26: 15-34
[Abstract]
[Full Text]
-
Moll, U. M., Slade, N.
(2004). p63 and p73: Roles in Development and Tumor Formation. Mol Cancer Res
2: 371-386
[Abstract]
[Full Text]
-
Xia, L., Paik, A., Li, J. J.
(2004). p53 Activation in Chronic Radiation-Treated Breast Cancer Cells: Regulation of MDM2/p14ARF. Cancer Res.
64: 221-228
[Abstract]
[Full Text]
-
Wiederschain, D., Kawai, H., Gu, J., Shilatifard, A., Yuan, Z.-M.
(2003). Molecular Basis of p53 Functional Inactivation by the Leukemic Protein MLL-ELL. Mol. Cell. Biol.
23: 4230-4246
[Abstract]
[Full Text]
-
Wang, W., Takimoto, R., Rastinejad, F., El-Deiry, W. S.
(2003). Stabilization of p53 by CP-31398 Inhibits Ubiquitination without Altering Phosphorylation at Serine 15 or 20 or MDM2 Binding. Mol. Cell. Biol.
23: 2171-2181
[Abstract]
[Full Text]
-
Bensaad, K., Le Bras, M., Unsal, K., Strano, S., Blandino, G., Tominaga, O., Rouillard, D., Soussi, T.
(2003). Change of Conformation of the DNA-binding Domain of p53 Is the Only Key Element for Binding of and Interference with p73. J. Biol. Chem.
278: 10546-10555
[Abstract]
[Full Text]
-
Zaika, A. I., Slade, N., Erster, S. H., Sansome, C., Joseph, T. W., Pearl, M., Chalas, E., Moll, U. M.
(2002). {Delta}Np73, A Dominant-Negative Inhibitor of Wild-type p53 and TAp73, Is Up-regulated in Human Tumors. J. Exp. Med.
196: 765-780
[Abstract]
[Full Text]
-
Kawai, H., Nie, L., Yuan, Z.-M.
(2002). Inactivation of NF-{kappa}B-Dependent Cell Survival, a Novel Mechanism for the Proapoptotic Function of c-Abl. Mol. Cell. Biol.
22: 6079-6088
[Abstract]
[Full Text]
-
Shimura, T., Inoue, M., Taga, M., Shiraishi, K., Uematsu, N., Takei, N., Yuan, Z.-M., Shinohara, T., Niwa, O.
(2002). p53-Dependent S-Phase Damage Checkpoint and Pronuclear Cross Talk in Mouse Zygotes with X-Irradiated Sperm. Mol. Cell. Biol.
22: 2220-2228
[Abstract]
[Full Text]
-
Gu, J., Nie, L., Wiederschain, D., Yuan, Z.-M.
(2001). Identification of p53 Sequence Elements That Are Required for MDM2-Mediated Nuclear Export. Mol. Cell. Biol.
21: 8533-8546
[Abstract]
[Full Text]
-
Gu, J., Nie, L., Kawai, H., Yuan, Z.-M.
(2001). Subcellular Distribution of p53 and p73 Are Differentially Regulated by MDM2. Cancer Res.
61: 6703-6707
[Abstract]
[Full Text]
-
Zilfou, J. T., Hoffman, W. H., Sank, M., George, D. L., Murphy, M.
(2001). The Corepressor mSin3a Interacts with the Proline-Rich Domain of p53 and Protects p53 from Proteasome-Mediated Degradation. Mol. Cell. Biol.
21: 3974-3985
[Abstract]
[Full Text]
-
Zhang, Y., Xiong, Y.
(2001). Control of p53 Ubiquitination and Nuclear Export by MDM2 and ARF. Cell Growth Differ.
12: 175-186
[Abstract]
[Full Text]
-
Wang, X. Q., Ongkeko, W. M., Lau, A. W. S., Leung, K. M., Poon, R. Y. C.
(2001). A Possible Role of p73 on the Modulation of p53 Level through MDM2. Cancer Res.
61: 1598-1603
[Abstract]
[Full Text]
-
Gu, J., Kawai, H., Wiederschain, D., Yuan, Z.-M.
(2001). Mechanism of Functional Inactivation of a Li-Fraumeni Syndrome p53 That Has a Mutation Outside of the DNA-binding Domain. Cancer Res.
61: 1741-1746
[Abstract]
[Full Text]
-
Rodriguez, M. S., Desterro, J. M. P., Lain, S., Lane, D. P., Hay, R. T.
(2000). Multiple C-Terminal Lysine Residues Target p53 for Ubiquitin-Proteasome-Mediated Degradation. Mol. Cell. Biol.
20: 8458-8467
[Abstract]
[Full Text]
-
Wiederschain, D., Gu, J., Yuan, Z.-M.
(2001). Evidence for a Distinct Inhibitory Factor in the Regulation of p53 Functional Activity. J. Biol. Chem.
276: 27999-28005
[Abstract]
[Full Text]
-
Calabro, V., Mansueto, G., Parisi, T., Vivo, M., Calogero, R. A., La Mantia, G.
(2002). The Human MDM2 Oncoprotein Increases the Transcriptional Activity and the Protein Level of the p53 Homolog p63. J. Biol. Chem.
277: 2674-2681
[Abstract]
[Full Text]